Key Highlights
- Moderna shares tumbled to close at $187.46 on October 6 as traders took profits following the WHO's downgraded plague risk assessment.
- Shares had rallied a day earlier on reports of suspected pneumonic plague cases in Russia circulating among traders.
- The WHO's lowered risk assessment removed much of the speculative case that had lifted vaccine-related stocks.
- Moderna is separately set to rejoin the Nasdaq-100 index on October 9.
Moderna (NASDAQ:MRNA) tumbled on Tuesday, closing at $187.46, as one of the steeper decliners in the S&P 500. Sources differed on the size of the drop, but all showed a sharp fall. The move was tied to profit-taking after the World Health Organization downgraded its assessment of the risk from a pneumonic plague outbreak to low.
The decline unwound part of a rally that began only a day earlier. On Monday evening, October 5, reports said Moderna, Vaxcyte (NASDAQ:PCVX) and Novavax (NASDAQ:NVAX) were trending among traders following reports of suspected pneumonic plague cases in Russia. Shares of Vaccine developers often jump on news of disease outbreaks, as investors bet on possible Demand for new shots or government contracts, and those moves can reverse just as quickly when health authorities signal that the threat is contained.
Why the WHO Call Mattered
Pneumonic plague is the most serious form of plague, a bacterial infection that can spread between people through the air. It is rare and usually treatable with antibiotics if caught early. The WHO's risk assessments carry weight with markets because they shape how governments and health agencies respond, including whether they consider emergency purchases of vaccines or treatments.
By lowering its assessment, the WHO removed much of the speculative case that had lifted vaccine stocks. Novavax also slid sharply on Tuesday, while Vaxcyte fell in premarket trading after launching $500 million stock and $500 million convertible offerings following a strong run on late-stage trial results.
Health Care Lagged a Record Day
Moderna's slide came on a day when the wider market was in a celebratory mood. The S&P 500 gained 44.98 points to a record close of 7,818.93, the Nasdaq Composite also closed at a record just under 27,600, and the Dow rose 253 points. Treasury yields eased and the VIX Volatility gauge dipped to about 15.
Health care, however, was the only S&P 500 sector to finish lower. Illumina (NASDAQ:ILMN) slid after hitting a 52-week high, Stryker (NYSE:SYK) slipped on news of a CEO succession plan, and a broad group of life-science tools makers including Thermo Fisher (NYSE:TMO), Danaher (NYSE:DHR) and IQVIA (NYSE:IQV) lost ground. Among smaller companies the weakness was even more pronounced, with only a small fraction of health-care stocks in the Russell 2000 advancing on the day.
Back in the Nasdaq-100
There was a structural note for Moderna amid the selling: the company is set to rejoin the Nasdaq-100 on October 9. Index inclusion typically brings buying from funds that track the benchmark, although such changes are usually anticipated once announced.
Moderna, best known for its mRNA-based COVID-19 vaccine, has been working to broaden its Business into other respiratory vaccines and newer areas such as cancer treatments. Its shares have often been volatile around public-health headlines, reflecting the market's tendency to tie the company to outbreak news.
Index Inclusion Is the Near-Term Marker
The first marker is Moderna's return to the Nasdaq-100 on October 9, which could bring index-related trading. Investors will also watch for further updates from health authorities on the suspected plague cases, since any change in the risk picture could again move vaccine stocks quickly.






Please wait processing your request...